ClinicalTrials.gg
CompletedNCT01808300Updated Aug 22, 2013

Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid.

A Phase 1 interventional study of Pregabalin 300mg, Thioctic acid 600mg in Healthy, sponsored by Unimed Pharmaceuticals. Completed. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-22.

Sponsored by Unimed Pharmaceuticals · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

A randomized, open-label, six-sequence, three-period, three-treatment, multiple dosing clinical trial to investigate the pharmacokinetic drug interaction between Pregabalin and Thioctic acid after oral administration in healthy male volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Unimed Pharmaceuticals is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Body weight ae least 50kg and (body mass index) within the range of 18 to 27kg/m2
  2. Provision of signed written
  3. Acceptable physical examination and clinical examination, during screening

Exclusion criteria

Exclusion Criteria:

  1. A subject with clinical evidence or history of hepatic (including carrier of hepatitis virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic, oncologic, psychiatric, or cardiovascular disease
  2. A subject with a history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug
  3. A subject with history of allergies including study drug (pregabalin or thioctic acid) or other drug allergies (aspirin, antibiotics, etc.), or history of allergies
  4. A subject whose lab test results are as follows: (SGOT), ALT(SGPT) > 1.5 x upper limit of reference range
  5. Presence or history of drug abuse or positive result in urine drug screening test
  6. Use any prescriptive medication, Korean traditional medication not considered acceptable by the clinical investigator during the last 14 days period before first dosing, or use any OTC medication not considered acceptable by the clinical investigator during the last 7 days period before first dosing (if used medication is considered acceptable by investigator, patients can be included)
  7. Participation in clinical trials of any drug within 60 days prior to the participation of the study
  8. Blood donation during 2 months or apheresis during 1 month before the study
  9. Use of alcohol over 21 units/weeks
  10. Smoker who smoke more than 10 cigarettes per day or who cannot stop smoking during the study period (from 24 hours before hospitalization to discharge)
  11. Use of caffeine drink during the study period(from 24 hours before hospitalization to discharge)
  12. A subject who takes grapefruit, grapefruit juice, or grapefruit-containing products during the study
  13. Judged to be inappropriate for the study by the investigator after reviewing clinical laboratory results or other reasons.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    A-B-C

    Drug will be administered to according to A-B-C sequence for 3 period.

    Drug: Pregabalin 300mg, Thioctic acid 600mg

  • Experimental
    A-C-B

    Drug will be administered to according to A-C-B sequence for 3 period.

    Drug: Pregabalin 300mg, Thioctic acid 600mg

  • Experimental
    B-C-A

    Drug will be administered to according to B-C-A sequence for 3 period.

    Drug: Pregabalin 300mg, Thioctic acid 600mg

  • Experimental
    B-A-C

    Drug will be administered to according to B-A-C sequence for 3 period.

    Drug: Pregabalin 300mg, Thioctic acid 600mg

  • Experimental
    C-A-B

    Drug will be administered to according to C-A-B sequence for 3 period.

    Drug: Pregabalin 300mg, Thioctic acid 600mg

  • Experimental
    C-B-A

    Drug will be administered to according to C-B-A sequence for 3 period.

    Drug: Pregabalin 300mg, Thioctic acid 600mg

Interventions

  • * A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days * B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days * C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B

06

What researchers measure

Primary outcomes

  1. AUCτ,ss / Cmax of pregabalin and thioctic acid

    Time frame: 2d (9d, 16d): 0h (predose:Thioctic acid), 12h (pre-dose:Pregabalin), 3d(10d, 17d): 0h (pre-dose), 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12h, 24h

Secondary outcomes

  1. Ctrough,ss / Tmax,ss / t½ / CL/F of pregabalin and thioctic acid

    Time frame: 2d (9d, 16d): 0h (predose:Thioctic acid), 12h (pre-dose:Pregabalin), 3d(10d, 17d): 0h (pre-dose), 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.25, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12h, 24h

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Rhee SJ, Lee H, Ahn LY, Lim KS, Yu KS. Lack of a Clinically Significant Pharmacokinetic Interaction Between Pregabalin and Thioctic Acid in Healthy Volunteers. Clin Ther. 2018 Oct;40(10):1720-1728.e2. doi: 10.1016/j.clinthera.2018.08.016. Epub 2018 Sep 18. PubMed 30241687 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Jul 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2013
First posted
Mar 11, 2013
Start
Feb 2013
Primary completionActual
Jul 2013
CompletionActual
Aug 2013
Last update
Aug 22, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01808300
Lead sponsor
Unimed Pharmaceuticals
Responsible party
Sponsor
First posted
Mar 11, 2013
Start date
Feb 2013
Primary completion
Jul 2013
Completion
Aug 2013
Last update
Aug 22, 2013

Study contacts

Kyung-Sang Yu
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion